X4 Pharmaceuticals, a fully integrated, commercial-stage biopharmaceutical company focused on rare immune disorders, announced today that it has secured $85,000,000 in investment capital from investors. This significant funding round highlights continued confidence in the company's strategic direction and its mission to address the substantial unmet medical needs of individuals living with challenging conditions.
Headquartered in Boston, Massachusetts, X4 Pharmaceuticals is dedicated to developing solutions to urgent and critical health concerns for populations whose challenges have been long overlooked. The company's portfolio includes its FDA-approved medication XOLREMDI® (mavorixafor), which is commercially available in the U.S. for its initial indication. Beyond this approval, X4 Pharmaceuticals is actively evaluating mavorixafor in additional potential indications, including an ongoing global, pivotal Phase 3 clinical trial for its use in chronic neutropenia. The successful completion of this funding round is a testament to the company's progress and the potential of its therapeutic candidates.
The $85,000,000 in raised capital is designated to support the company's strategic growth initiatives. These plans include enhancing the commercialization efforts for XOLREMDI®, ensuring broader patient access, and further advancing its robust clinical development pipeline. A key focus will be supporting the ongoing Phase 3 trial for chronic neutropenia, which represents a significant opportunity. The investment will also strengthen general operational capabilities and research activities as X4 Pharmaceuticals works to expand its impact within the rare immune disorder community.
Looking ahead, this substantial financing positions X4 Pharmaceuticals to accelerate its efforts in bringing innovative therapies to patients who need them most. The company plans to continue its focus on developing and delivering solutions that address critical health concerns, reinforcing its commitment to sustained growth and improving patient outcomes for the rare immune disorder community.
